newsfilter
← Latest News
PR Newswire·

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

  • Viking Therapeutics presented new VENTURE trial data at ObesityWeek 2026 regarding subcutaneous VK2735, a dual GLP-1 & GIP receptor agonist.
  • 74% of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks compared to 15% on placebo.
  • No VK2735-treated participants experienced an increase in BMI category, while 87% of placebo participants with Class I obesity showed no change.
  • Participants achieving BMI category improvement showed greater reductions in waist circumference, fasting insulin, glucose, blood pressure, total cholesterol, triglycerides, & LDL-C than those without BMI changes.
  • Previous VENTURE results indicated mean body weight reductions up to 14.7% from baseline, with 88% of treatment groups achieving ≥10% weight loss versus 4% for placebo.
  • The VANQUISH-2 Phase 3 study evaluating subcutaneous VK2735 in adults with overweight/obesity & type 2 diabetes is ongoing, with results expected in 2027.
  • The VANQUISH program consists of two 78-week, randomized, double-blind trials assessing weight loss efficacy & safety of once-weekly subcutaneous VK2735.
  • VK2735 demonstrated an encouraging safety profile with 92% of drug-related adverse events categorized as mild or moderate.
  • Viking is also developing other obesity programs including VK3019, VK2809, & VK0214 alongside oral & subcutaneous formulations of VK2735.
Company
Viking Therapeutics, Inc
Keywords
Viking Therapeutics, Inc